Trial Profile

HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid Tumours

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HMBD 001 (Primary) ; Antineoplastics
Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; First in man; Therapeutic Use

11 Aug 2025 Planned End Date changed from 1 Sep 2026 to 1 Nov 2025.
11 Aug 2025 Planned primary completion date changed from 1 Sep 2026 to 1 Nov 2025.
11 Aug 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com